Literature DB >> 22082786

The Ottawa and Kingston (OaK) Birth Cohort: development and achievements.

Mark C Walker1, Sara A Finkelstein, Ruth Rennicks White, Svetlana Shachkina, Graeme N Smith, Shi Wu Wen, Marc Rodger.   

Abstract

OBJECTIVE: The Ottawa and Kingston (OaK) Birth Cohort collected data on maternal and infant genetic and epidemiologic variables in order to (1) explore the association between folate supplementation or thrombophilias and adverse, placenta-mediated pregnancy outcomes; (2) create a biobank of maternal and infant biological and genetic samples; and (3) stimulate future research using this cohort data.
METHODS: A prospective cohort design was used to collect mother and infant data. Women were recruited at 12 to 20 weeks' gestation, during prenatal care visits at The Ottawa Hospital and Kingston General Hospital from October 2002 to April 2009. Data on maternal and infant demographics, maternal health, obstetrical history, and pregnancy outcomes were collected. Testing was done for biological/serological markers associated with adverse pregnancy outcomes. Maternal and cord blood samples were biobanked.
RESULTS: A total of 8085 mothers were recruited to the OaK Birth Cohort. Analysis of the cohort data showed that taking multivitamin supplements containing folic acid was associated with a reduced risk of preeclampsia (aOR 0.37; 95% CI 0.18 to 0.75). The majority of participants agreed to have their genetic/biological samples biobanked (samples collected for n = 7241 mothers, n = 2175 infants) and to be re-contacted regarding future research opportunities.
CONCLUSION: Birth cohorts are a useful tool in determining associations between risk factors and adverse maternal and fetal outcomes, and can serve as a repository of data for future research. Creating strong research partnerships helped enhance financial resources and increase participant recruitment potential. Epidemiological and biobanked data and samples from the OaK Birth Cohort are available for use by other investigators.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082786     DOI: 10.1016/s1701-2163(16)35080-0

Source DB:  PubMed          Journal:  J Obstet Gynaecol Can        ISSN: 1701-2163


  10 in total

1.  Generation and validation of a universal perinatal database and biospecimen repository: PeriBank.

Authors:  K M Antony; P Hemarajata; J Chen; J Morris; C Cook; D Masalas; M Gedminas; A Brown; J Versalovic; K Aagaard
Journal:  J Perinatol       Date:  2016-09-15       Impact factor: 2.521

2.  Detection of in utero Exposure to Cannabis in Paired Umbilical Cord Tissue and Meconium by Liquid Chromatography-Tandem Mass Spectrometry.

Authors:  Triniti L Jensen; Fang Wu; Gwendolyn A McMillin
Journal:  Clin Mass Spectrom       Date:  2019-01-24

Review 3.  Recruitment and retention of pregnant women in prospective birth cohort studies: A scoping review and content analysis of the literature.

Authors:  Ellen Goldstein; Ludmila N Bakhireva; Kendra Nervik; Shelbey Hagen; Alyssa Turnquist; Aleksandra E Zgierska; Lidia Enriquez Marquez; Ryan McDonald; Jamie Lo; Christina Chambers
Journal:  Neurotoxicol Teratol       Date:  2021-03-22       Impact factor: 3.763

4.  A combined supplementation of omega-3 fatty acids and micronutrients (folic acid, vitamin B12) reduces oxidative stress markers in a rat model of pregnancy induced hypertension.

Authors:  Nisha G Kemse; Anvita A Kale; Sadhana R Joshi
Journal:  PLoS One       Date:  2014-11-18       Impact factor: 3.240

Review 5.  Nutraceuticals and Hypertensive Disorders in Pregnancy: The Available Clinical Evidence.

Authors:  Silvia Fogacci; Federica Fogacci; Arrigo F G Cicero
Journal:  Nutrients       Date:  2020-01-31       Impact factor: 5.717

6.  Validation of Canadian mothers' recall of events in labour and delivery with electronic health records.

Authors:  Uilst Bat-Erdene; Amy Metcalfe; Sheila W McDonald; Suzanne C Tough
Journal:  BMC Pregnancy Childbirth       Date:  2013-01-31       Impact factor: 3.007

7.  The All Our Babies pregnancy cohort: design, methods, and participant characteristics.

Authors:  Sheila W McDonald; Andrew W Lyon; Karen M Benzies; Deborah A McNeil; Stephen J Lye; Siobhan M Dolan; Craig E Pennell; Alan D Bocking; Suzanne C Tough
Journal:  BMC Pregnancy Childbirth       Date:  2013-01-31       Impact factor: 3.007

8.  Prevention of congenital malformations and other adverse pregnancy outcomes with 4.0 mg of folic acid: community-based randomized clinical trial in Italy and the Netherlands.

Authors:  Renata Bortolus; Fenneke Blom; Francesca Filippini; Mireille N M van Poppel; Emanuele Leoncini; Denhard J de Smit; Pier Paolo Benetollo; Martina C Cornel; Hermien E K de Walle; Pierpaolo Mastroiacovo
Journal:  BMC Pregnancy Childbirth       Date:  2014-05-13       Impact factor: 3.007

9.  Comparison of risk factors and outcomes of gestational hypertension and pre-eclampsia.

Authors:  Minxue Shen; Graeme N Smith; Marc Rodger; Ruth Rennicks White; Mark C Walker; Shi Wu Wen
Journal:  PLoS One       Date:  2017-04-24       Impact factor: 3.240

10.  Effect of high dose folic acid supplementation in pregnancy on pre-eclampsia (FACT): double blind, phase III, randomised controlled, international, multicentre trial.

Authors:  Shi Wu Wen; Ruth Rennicks White; Natalie Rybak; Laura M Gaudet; Stephen Robson; William Hague; Donnette Simms-Stewart; Guillermo Carroli; Graeme Smith; William D Fraser; George Wells; Sandra T Davidge; John Kingdom; Doug Coyle; Dean Fergusson; Daniel J Corsi; Josee Champagne; Elham Sabri; Tim Ramsay; Ben Willem J Mol; Martijn A Oudijk; Mark C Walker
Journal:  BMJ       Date:  2018-09-12
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.